Presentation to be webcast on www.exelixis.com
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Nov. 25, 2014--
Exelixis, Inc. (NASDAQ:EXEL) today announced that Michael M. Morrissey,
Ph.D., the company’s president and chief executive officer, will provide
an overview of the company at the Piper Jaffray 26th Annual
Healthcare Conference taking place December 2-3 in New York. The
Exelixis presentation is scheduled for 1:30 p.m. EST/10:30 a.m. PST on
Tuesday, December 2, 2014.
The presentation will be webcast live and may be accessed via the Event
Calendar page under Investors & Media at www.exelixis.com.
Please connect to the company’s website at least 15 minutes prior to the
presentation to ensure adequate time for any software download that may
be required to listen to the webcast. A replay will also be available at
the same location for 14 days.
About Exelixis
Exelixis, Inc. is a biopharmaceutical company committed to developing
small molecule therapies for the treatment of cancer. Exelixis is
focusing its development and commercialization efforts primarily on
COMETRIQ® (cabozantinib), its wholly-owned inhibitor of multiple
receptor tyrosine kinases. Another Exelixis-discovered compound,
cobimetinib, a highly selective inhibitor of MEK, is being evaluated
by Roche and Genentech (a member of the Roche Group) in a broad
development program under a collaboration with Exelixis. For more
information, please visit the company’s web site at www.exelixis.com.
Exelixis, the Exelixis logo, and COMETRIQ are registered U.S.
trademarks.
Source: Exelixis, Inc.
Exelixis, Inc.
Susan Hubbard, 650-837-8194
Investor
Relations & Corporate Communications
shubbard@exelixis.com